{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:51:41Z","timestamp":1791042701436,"version":"4.1.0"},"reference-count":82,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary aldosteronism affects 5\u201313% of patients with hypertension. Patients with hypertension and hypokalemia and most patients with treatment-resistant hypertension should undergo screening for primary aldosteronism with a plasma aldosterone concentration to plasma renin activity ratio. A high plasma aldosterone concentration to plasma renin activity ratio is a positive screening test result, a finding that warrants confirmatory testing. For those patients that want to pursue a surgical cure, the accurate distinction between the subtypes (unilateral vs. bilateral adrenal disease) of primary aldosteronism is a critical step. The subtype evaluation may require one or more tests, the first of which is imaging the adrenal glands with computed tomography, followed by selective use of adrenal venous sampling. Because of the deleterious cardiovascular effects of aldosterone, normalization of circulating aldosterone or aldosterone receptor blockade should be part of the management plan for all patients with primary aldosteronism. Unilateral laparoscopic adrenalectomy is an excellent treatment option for patients with unilateral aldosterone-producing adenoma. Bilateral idiopathic hyperaldosteronism should be treated medically. In addition, aldosterone-producing adenoma patients may be treated medically if the medical treatment includes mineralocorticoid receptor blockade.<\/jats:p>","DOI":"10.1210\/en.2003-0279","type":"journal-article","created":{"date-parts":[[2003,5,14]],"date-time":"2003-05-14T04:48:44Z","timestamp":1052887724000},"page":"2208-2213","source":"Crossref","is-referenced-by-count":291,"title":["Minireview: Primary Aldosteronism\u2014Changing Concepts in Diagnosis and Treatment"],"prefix":"10.1210","volume":"144","author":[{"suffix":"Jr.","given":"William F.","family":"Young","sequence":"first","affiliation":[{"name":"Professor of Medicine, Mayo Medical School; Consultant, Division of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071620294561900_R1","first-page":"3","article-title":"Presidential address. Part I, Painting background. Part II, Primary aldosteronism, a new clinical syndrome.","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"2020071620294561900_R2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimeric 11\u03b2-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"key":"2020071620294561900_R3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1749-6632.2002.tb04414.x","article-title":"New genetic insights in familial hyperaldosteronism.","volume":"970","author":"Jackson","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2020071620294561900_R4","first-page":"187","article-title":"The incidence rate of phaeochromocytoma and Conn\u2019s syndrome in Denmark, 1977\u20131981.","volume":"2","author":"Andersen","year":"1988","journal-title":"J Hum Hypertens"},{"key":"2020071620294561900_R5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2307\/3349261","article-title":"Evaluation of the hypertensive patient with emphasis on detecting curable causes.","volume":"47","author":"Gifford Jr","year":"1969","journal-title":"Milbank Mem Fund Q"},{"key":"2020071620294561900_R6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.7326\/0003-4819-66-6-1079","article-title":"Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism.","volume":"66","author":"Kaplan","year":"1967","journal-title":"Ann Intern Med"},{"key":"2020071620294561900_R7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.1987.00370070103015","article-title":"Secondary hypertension in a blood pressure clinic.","volume":"147","author":"Sinclair","year":"1987","journal-title":"Arch Intern Med"},{"key":"2020071620294561900_R8","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archinte.1996.00440100086010","article-title":"Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients.","volume":"156","author":"Abdelhamid","year":"1996","journal-title":"Arch Intern Med"},{"key":"2020071620294561900_R9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00004872-199405000-00015","article-title":"The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients.","volume":"12","author":"Anderson","year":"1994","journal-title":"J Hypertens"},{"key":"2020071620294561900_R10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0895-7061(02)02969-2","article-title":"High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.","volume":"15","author":"Rossi","year":"2002","journal-title":"Am J Hypertens"},{"key":"2020071620294561900_R11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1749-6632.2002.tb04413.x","article-title":"Primary aldosteronism: management issues.","volume":"970","author":"Young Jr","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2020071620294561900_R12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension.","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"2020071620294561900_R13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism.","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"2020071620294561900_R14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch Intern Med"},{"key":"2020071620294561900_R15","first-page":"109","article-title":"Screening and diagnosis of hypertension forms secondary to excess of mineralocorticoid.","volume":"39","author":"Vallotton","year":"1998","journal-title":"Rev Fr Endocrinol Clin"},{"key":"2020071620294561900_R16","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jcem-73-5-952","article-title":"Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.","volume":"73","author":"McKenna","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.jhh.1000444","article-title":"Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism.","volume":"11","author":"Ignatowska-Switalska","year":"1997","journal-title":"J Hum Hypertens"},{"key":"2020071620294561900_R18","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.1993.00410180075008","article-title":"The diagnosis of primary aldosteronism and separation of two major subtypes.","volume":"153","author":"Weinberger","year":"1993","journal-title":"Arch Intern Med"},{"key":"2020071620294561900_R19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2020071620294561900_R20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-8529(02)00013-0","article-title":"Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature.","volume":"31","author":"Montori","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071620294561900_R21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","article-title":"High incidence of primary aldosteronism in 199 patients referred with hypertension.","volume":"21","author":"Gordon","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2020071620294561900_R22","first-page":"731","article-title":"Screening of a population of young hypertensives for primary hyperaldosteronism.","volume":"8","author":"Kumar","year":"1994","journal-title":"J Hum Hypertens"},{"key":"2020071620294561900_R23","first-page":"17","article-title":"Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients.","volume":"45","author":"Kreze","year":"1999","journal-title":"Vnitr Lek"},{"key":"2020071620294561900_R24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","article-title":"High prevalence of primary aldosteronism in the Tayside hypertension clinic population.","volume":"14","author":"Lim","year":"2000","journal-title":"J Hum Hypertens"},{"key":"2020071620294561900_R25","first-page":"2854","article-title":"Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.","volume":"85","author":"Loh","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R26","first-page":"1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0895-7061(02)02318-X","article-title":"Prevalence of unrecognized primary aldosteronism in essential hypertension.","volume":"15","author":"Schwartz","year":"2002","journal-title":"Am J Hypertens"},{"key":"2020071620294561900_R28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1440-1681.1985.tb02641.x","article-title":"Is aldosterone\/renin ratio useful to screen a hypertensive population for primary aldosteronism?","volume":"12","author":"Hamlet","year":"1985","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2020071620294561900_R29","first-page":"200","article-title":"Incidence of primary hyperaldosteronism in hospitalized hypertensive patients.","volume":"100","author":"Lazurova","year":"1999","journal-title":"Bratisl Lek Listy"},{"key":"2020071620294561900_R30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","article-title":"Potentially high prevalence of primary aldosteronism in a primary-care population.","volume":"353","author":"Lim","year":"1999","journal-title":"Lancet"},{"key":"2020071620294561900_R31","first-page":"800","article-title":"High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension [Alta prevalencia de hiperaldosteronismo primario no diagnosticado en hipertension catalogados como esenciales].","volume":"127","author":"Mosso","year":"1999","journal-title":"Rev Med Chil"},{"key":"2020071620294561900_R32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2265.1998.00608.x","article-title":"Screening for primary aldosteronism with a logistic multivariate discriminant analysis.","volume":"49","author":"Rossi","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071620294561900_R33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00060793-200106000-00004","article-title":"Establishing a diagnosis of primary aldosteronism.","volume":"8","author":"Moneva","year":"2001","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"2020071620294561900_R34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00268-001-0033-4","article-title":"Primary aldosteronism: are we diagnosing and operating too few patients?","volume":"25","author":"Gordon","year":"2001","journal-title":"World J Surg"},{"key":"2020071620294561900_R35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00045415-199907000-00012","article-title":"Primary aldosteronism: a common and curable form of hypertension.","volume":"7","author":"Young Jr","year":"1999","journal-title":"Cardiol Rev"},{"key":"2020071620294561900_R36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.HYP.0000014324.68506.CA","article-title":"Diagnostic value of the post-captopril test in primary aldosteronism.","volume":"39","author":"Castro","year":"2002","journal-title":"Hypertension"},{"key":"2020071620294561900_R37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11906-002-0014-5","article-title":"Functional tests for primary aldosteronism: value of captopril suppression.","volume":"4","author":"Racine","year":"2002","journal-title":"Curr Hypertens Rep"},{"key":"2020071620294561900_R38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(00)04223-9","article-title":"Cautions over the current epidemic of primary aldosteronism.","volume":"357","author":"Kaplan","year":"2001","journal-title":"Lancet"},{"key":"2020071620294561900_R39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.jhh.1001321","article-title":"Primary aldosteronism, a common entity? The myth persists.","volume":"16","author":"Padfield","year":"2002","journal-title":"J Hum Hypertens"},{"key":"2020071620294561900_R40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","article-title":"Primary aldosteronism: factors associated with normalization of blood pressure after surgery.","volume":"135","author":"Sawka","year":"2001","journal-title":"Ann Intern Med"},{"key":"2020071620294561900_R41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0889-8529(18)30425-0","article-title":"Primary aldosteronism: diagnostic evaluation.","volume":"17","author":"Young Jr","year":"1988","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071620294561900_R42","first-page":"460","article-title":"Incidentally discovered adrenal masses.","volume":"16","author":"Kloos","year":"1995","journal-title":"Endocr Rev"},{"key":"2020071620294561900_R43","doi-asserted-by":"crossref","first-page":"877","DOI":"10.7326\/0003-4819-121-11-199412010-00010","article-title":"Diagnosis and treatment of primary aldosteronism.","volume":"121","author":"Blumenfeld","year":"1994","journal-title":"Ann Intern Med"},{"key":"2020071620294561900_R44","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0039-6060(96)80033-X","article-title":"Primary aldosteronism: adrenal venous sampling.","volume":"120","author":"Young Jr","year":"1996","journal-title":"Surgery"},{"key":"2020071620294561900_R45","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.86.3.7287","article-title":"Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases.","volume":"86","author":"Rossi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R46","first-page":"1066","article-title":"Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism.","volume":"86","author":"Magill","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1148\/radiology.198.2.8596821","article-title":"Hyperaldosteronism: sampling the adrenal veins.","volume":"198","author":"Doppman","year":"1996","journal-title":"Radiology"},{"key":"2020071620294561900_R48","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020071620294561900_R49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system.","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2020071620294561900_R50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00045415-200203000-00008","article-title":"Aldosterone as a mediator in cardiovascular injury.","volume":"10","author":"Stier Jr","year":"2002","journal-title":"Cardiol Rev"},{"key":"2020071620294561900_R51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"key":"2020071620294561900_R52","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricles in experimental hypertension.","volume":"67","author":"Brilla","year":"1990","journal-title":"Circ Res"},{"key":"2020071620294561900_R53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071620294561900_R54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00003495-200262050-00001","article-title":"Rationale for the use of aldosterone antagonists in congestive heart failure.","volume":"62","author":"Rocha","year":"2002","journal-title":"Drugs"},{"key":"2020071620294561900_R55","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","article-title":"Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.","volume":"324","author":"Alderman","year":"1991","journal-title":"N Engl J Med"},{"key":"2020071620294561900_R56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.","volume":"95","author":"Vaughan","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071620294561900_R57","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1172\/JCI118312","article-title":"Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.","volume":"96","author":"Kerins","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071620294561900_R58","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R59","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1.","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"2020071620294561900_R60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1210\/jcem.87.2.7980","article-title":"Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.","volume":"87","author":"Sawathiparnich","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071620294561900_R61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1291\/hypres.20.85","article-title":"Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.","volume":"20","author":"Tanabe","year":"1997","journal-title":"Hypertens Res"},{"key":"2020071620294561900_R62","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma.","volume":"95","author":"Rossi","year":"1997","journal-title":"Circulation"},{"key":"2020071620294561900_R63","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/01.HYP.29.3.723","article-title":"Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism.","volume":"29","author":"Shigematsu","year":"1997","journal-title":"Hypertension"},{"key":"2020071620294561900_R64","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"2020071620294561900_R65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0895-7061(96)00031-3","article-title":"Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension.","volume":"9","author":"Yoshihara","year":"1996","journal-title":"Am J Hypertens"},{"key":"2020071620294561900_R66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0895-7061(01)02331-7","article-title":"Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension.","volume":"15","author":"Goldkorn","year":"2002","journal-title":"Am J Hypertens"},{"key":"2020071620294561900_R67","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.HYP.28.5.785","article-title":"Vascular hypertrophy and remodeling in secondary hypertension.","volume":"28","author":"Rizzoni","year":"1996","journal-title":"Hypertension"},{"key":"2020071620294561900_R68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0735-1097(98)00322-2","article-title":"Relations between cardiac and vascular structure in patients with primary and secondary hypertension.","volume":"32","author":"Rizzoni","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2020071620294561900_R69","doi-asserted-by":"crossref","first-page":"I164","DOI":"10.1161\/01.HYP.23.1_Suppl.I164","article-title":"Myocardial scintigraphic characteristics in patients with primary aldosteronism","volume":"23","author":"Abe","year":"1994","journal-title":"Hypertension"},{"key":"2020071620294561900_R70","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/archsurg.1996.01430180072015","article-title":"Factors influencing outcome of surgery for primary aldosteronism.","volume":"131","author":"Celen","year":"1996","journal-title":"Arch Surg"},{"key":"2020071620294561900_R71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(05)64028-1","article-title":"Laparoscopic management of primary aldosteronism: clinical experience with 212 cases.","volume":"169","author":"Meria","year":"2003","journal-title":"J Urol"},{"key":"2020071620294561900_R72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1291\/hypres.25.11","article-title":"Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy.","volume":"25","author":"Fukudome","year":"2002","journal-title":"Hypertens Res"},{"key":"2020071620294561900_R73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/000313480206800307","article-title":"Primary aldosteronism in the era of laparoscopic adrenalectomy.","volume":"68","author":"Rossi","year":"2002","journal-title":"Am Surg"},{"key":"2020071620294561900_R74","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1365-2168.2002.02261.x","article-title":"Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism.","volume":"89","author":"Sywak","year":"2002","journal-title":"Br J Surg"},{"key":"2020071620294561900_R75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism.","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"key":"2020071620294561900_R76","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension.","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"2020071620294561900_R77","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1345\/aph.1C027","article-title":"Eplerenone: a novel selective aldosterone blocker.","volume":"36","author":"Zillich","year":"2002","journal-title":"Ann Pharmacother"},{"key":"2020071620294561900_R78","first-page":"650","article-title":"Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro.","volume":"240","author":"De Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071620294561900_R79","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"2020071620294561900_R80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"2020071620294561900_R81","doi-asserted-by":"crossref","first-page":"I207","DOI":"10.1161\/01.HYP.11.2_Pt_2.I207","article-title":"Clinical implications of primary aldosteronism with resistant hypertension","volume":"11","author":"Bravo","year":"1988","journal-title":"Hypertension"},{"key":"2020071620294561900_R82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/1043-2760(94)90090-6","article-title":"Renin-independent hypermineralocorticoidism.","volume":"5","author":"Young Jr","year":"1994","journal-title":"Trends Endocrinol Metab"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/144\/6\/2208\/9295908\/endo2208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/144\/6\/2208\/9295908\/endo2208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T08:28:05Z","timestamp":1682497685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/144\/6\/2208\/2880517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,1]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2003-0279","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,1]]}}}